Overview

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
Phase:
Phase 2
Details
Lead Sponsor:
BioVie Inc.
Treatments:
Lypressin
Terlipressin